Cosmo Pharmaceuticals NV
SIX:COPN
| US |
|
Microsoft Corp
NASDAQ:MSFT
|
Technology
|
| FR |
|
L'Air Liquide Societe Anonyme pour l'Etude et l'Exploitation des Procedes Georges Claude SA
PAR:AI
|
Chemicals
|
| FR |
|
LVMH Moet Hennessy Louis Vuitton SE
PAR:MC
|
Textiles, Apparel & Luxury Goods
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
38.9
79.9
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
|
|
Microsoft Corp
NASDAQ:MSFT
|
US |
|
|
L'Air Liquide Societe Anonyme pour l'Etude et l'Exploitation des Procedes Georges Claude SA
PAR:AI
|
FR |
|
|
LVMH Moet Hennessy Louis Vuitton SE
PAR:MC
|
FR |
This alert will be permanently deleted.
Cosmo Pharmaceuticals NV
P/B
Price to Book Value
Price to Book Value (P/B) ratio is a valuation multiple that measures the market's valuation of a company relative to its book value. The P/B ratio is only considered useful in practice when applied to capital-intensive businesses.
| Market Cap | P/B | ||||
|---|---|---|---|---|---|
| IE |
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
1B CHF | 2.2 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -21 763 099 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
710.5B USD | 49.9 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 583.1 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
3.3T DKK | 27.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
373.5B USD | 5.3 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
251.1B USD | 5.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
202.7B CHF | 6.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
183.3B CHF | 5.2 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
162.4B GBP | 5.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
146B USD | -35.4 |
P/B Forward Multiples
Forward P/B multiple is a version of the P/B ratio that uses forecasted equity for the P/B calculation. 1-Year, 2-Years, and 3-Years forwards use equity forecasts for 1, 2, and 3 years ahead, respectively.
You don't have any saved screeners yet
